Skip to content

Role of Bile Acids in the Pathogenesis of Cirrhotic Cardiomyopathy

Role of Bile Acids in the Pathogenesis of Cirrhotic Cardiomyopathy - Bile Acids CCM

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00033107
Enrollment
1000
Registered
2023-11-28
Start date
2023-11-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Corrhosis (K74) K74

Interventions

Group 1: Existing Cirrhotic Cardiomyopathy Group 2: No existing Cirrhotic Cardiomyopathy

Sponsors

Klinik für Kardiologie, Pneumologie und Angiologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: - Male, female, diverse patients from the Clinic for Cardiology, Pneumology and Angiology who receive an echocardiographic examination for clinical reasons, with and without existing liver disease - Male, female, various patients from the Clinic for Cardiology, Pneumology and Angiology who receive an echocardiographic examination for clinical reasons with existing liver disease with indication for TIPPS or liver transplantation. - Persons who are able to understand and follow the instructions of the study personnel - Written informed consent

Exclusion criteria

Exclusion criteria: - Age < 18 years - Lack of written consent to participate in the study

Design outcomes

Primary

MeasureTime frame
Cardiac function measured by echocardiography before and up to 7 months after TIPS or liver transplantation

Secondary

MeasureTime frame
Bile acids measured by mass spectrometry before and up to 7 months after TIPS or liver transplantation

Countries

Germany

Contacts

Public ContactLisa Dannenberg

Klinik für Kardiologie, Pneumologie und Angiologie

LISA.DANNENBERG@MED.UNI-DUESSELDORF.DE0221811880

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026